Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

  * Pyzchiva(®) approved as one of first ustekinumab biosimilars in Europe
  * EC approval based on robust development program confirming match to
    reference medicine in terms of safety, efficacy and quality

* Sandoz remains committed to accelerating access to potentially life-changing treatments and continues strengthening immunology portfolio
Basel, April 22, 2024 - Sandoz, the global leader in generic and biosimilar
medicines, today announces that the European Commission (EC) has granted
marketing authorization for Pyzchiva(®* )(biosimilar ustekinumab), developed and
registered by Samsung Bioepis. Pyzchiva(® )is a key biosimilar value driver for
the company over the mid-term and this approval is a major step in advancing
Sandoz growth strategy.
Pyzchiva(® )is approved as a biologic therapy within gastroenterology,
dermatology, and rheumatology.(1)
Rebecca Guntern, President Sandoz Europe, said: "Chronic inflammatory diseases
affect millions of people around the world and can have a profoundly negative
impact on their quality of life. This approval is a crucial step towards
offering European patients an additional safe and effective treatment option and
further demonstrates our commitment to pioneer access to potentially life-
changing medicines."
The comprehensive regulatory submission package included extensive analytical,
preclinical, and clinical data, including a Phase I PK/PD study and a Phase III
confirmatory study.
Sandoz entered into a development and commercialization agreement for biosimilar
ustekinumab with Samsung Bioepis in September 2023. Under the terms of the
agreement, Sandoz has the right to commercialize Pyzchiva(® )in the US, Canada,
the European Economic Area (EEA), Switzerland, and the UK. Samsung Bioepis
remains responsible for development, registration, intellectual property,
manufacturing and supply.
* Pyzchiva(®) is a trademark of Samsung Bioepis Co. Ltd.
About Pyzchiva(®) (ustekinumab)
Pyzchiva(®) (ustekinumab) has been developed to match the reference medicine, a
monoclonal antibody medication to interleukin (IL)-12/23 for the treatment of
autoimmune disorders including within gastroenterology, dermatology, and
rheumatology.( 1)
Disclaimer
This Media Release contains forward-looking statements, which offer no guarantee
with regard to future performance. These statements are made on the basis of
management's views and assumptions regarding future events and business
performance at the time the statements are made. They are subject to risks and
uncertainties including, but not confined to, future global economic conditions,
exchange rates, legal provisions, market conditions, activities by competitors
and other factors outside of the control of Sandoz. Should one or more of these
risks or uncertainties materialize or should underlying assumptions prove
incorrect, actual outcomes may vary materially from those forecasted or
expected. Each forward-looking statement speaks only as of the date of the
particular statement, and Sandoz undertakes no obligation to publicly update or
revise any forward-looking statements, except as required by law.
References
1. European Medicines Agency (EMA). Pzychiva(®) (ustekinumab): Prescribing

    Information. Available
    from: https://www.ema.europa.eu/en/medicines/human/EPAR/pyzchiva (Last
    accessed April 2024).

2. International Federation of Psoriasis Associations (IFPA). Speaking up for

    psoriatic disease in Europe. Available at: https://cms.ifpa-
    pso.com/tools/20072022_IFPA-FORUM_Briefing-Book_Speaking-up.pdf (Last
    accessed April 2024).

3. Frede N, et al. Psoriasis and Psoriatic Arthritis Have a Major Impact on

    Quality of Life and Depressive Symptoms: A Cross-Sectional Study of 300
    Patients. Rheumatology and Therapy. 2023;10: 1655-1668. doi:
    10.1007/s40744-023-00602-9.

4. Kumar A, et al. Crossing barriers: the burden of inflammatory bowel disease

    across Western Europe. Therapeutic Advances in Gastroenterology. 2023;16.
    doi: 10.1177/17562848231218615.

5. Burisch J. et al. The burden of inflammatory bowel disease in

    Europe, Journal of Crohn's and Colitis, Volume 7, Issue 4, May 2013, P.
    322-337

6. Pulley J, et al. Malnutrition and quality of life among adult inflammatory

    bowel disease patients. JGH Open. 2019;4(3): 454-460. doi:
    10.1002/jgh3.12278.

About Sandoz
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar
medicines, with a growth strategy driven by its Purpose: pioneering access for
patients. More than 20,000 people of more than 100 nationalities work together
to ensure 800 million patient treatments are provided by Sandoz, generating
substantial global healthcare savings and an even larger social impact. Its
leading portfolio of approximately 1,500 products addresses diseases from the
common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its
heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in
1929, the world's first oral penicillin in 1951, and the first biosimilar in
2006. In 2023, Sandoz recorded sales of USD 9.6 billion.
-------------------------------------------------------------------
Global Media Relations contacts Investor Relations contacts
-------------------------------------------------------------------
Global.MediaRelations@sandoz.com Investor.Relations@sandoz.com
-------------------------------------------------------------------

  Joerg E. Allgaeuer                 Karen M. King
  +49 171 838 4838                   +1 609 722 0982

-------------------------------------------------------------------

  Chris Lewis                        Laurent de Weck
  +49 174 244 9501                   +41 79 795 7364

-------------------------------------------------------------------Â